Cancer treatment causes 'financial toxicity' even for insured patients, leading some to skip medication.
Original statement
No Arabic original wording available.
Translation
Cancer treatment causes 'financial toxicity' even for insured patients, leading some to skip medication.
Origin
- Source status
- Archive editors
- Attribution
- Archive bibliography (study listed without interpretation)
- Origin
- https://eltayebat.com/rule/chemo-radiation/
- Attribution uncertainty
- Written by archive operators; not attributed to Elawady.
- Population concerned
Insured US cancer patients
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Financial burden of cancer treatment.
2. What is demonstrably correct?
42% of insured US patients seeking copay aid reported significant/catastrophic burden; 20-24% skipped or under-filled prescriptions (A-CHM-19).
3. What is wrong or exaggerated?
The data are US-specific and from a selected population; they are not evidence that treatment itself is harmful.
4. What remains unclear?
Situation in Egypt and Germany.
5. Which studies support it?
6. Which studies contradict it?
None identified; the finding comes from a single US pilot survey in a selected sample (A-CHM-19), and no contradicting study was reviewed.
7. What applies to Germany and Europe?
Statutory health insurance in Germany limits out-of-pocket costs (not quantified here).
8. What is known about Egypt?
Out-of-pocket costs in Egypt not reviewed.
9. What practical conclusion is appropriate?
Ask about social and financial support services.
Assessment details
- Rationale for certainty of evidence
Single US pilot survey in a selected sample; plausible and consistent with wider literature (not reviewed).
- Regional transferability
Low.
- Regional scope of the claim
- depends on production conditions
- Last reviewed
- 25 October 2026 provisional
In plain language
Cancer treatment can be expensive. In a US survey of insured patients, many reported heavy financial strain and some skipped medicines. This depends strongly on the health system.
Studies on this claim
Studies supporting the claim (1)
-
Cancer treatment costs strain even insured US patients
Zafar SY et al.. Oncologist 2013 · PMID 23442307 · DOI 10.1634/theoncologist.2012-0279Cross-sectional studycited by the Tayebat archiveabstract only checked42% reported a heavy financial burden and many skipped medicines to save money.
Financial toxicity
Does the study support the specific claim? Yes · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Describe financial toxicity.
- How was the study done?
Survey.
- How many people, animals or samples were studied?
254.
- What was actually found?
High burden.
- How large was the observed effect?
42% significant burden.
- What do the results mean in everyday life?
Ask about financial support services.
- What are the study's limitations?
Selected sample.
- What does it say about Elawady's specific claim?
Supports.
- Do the results apply to Germany and Europe?
Low.
- What can explicitly not be concluded from this study?
Situation in Germany/Egypt.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
Statutory health insurance in Germany limits out-of-pocket costs (not quantified here).
Egypt
Out-of-pocket costs in Egypt not reviewed.
What applies in my country?
General scientific assessment
Mostly true Financial toxicity is real in the US; transferability is limited.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.. Zafar SY et al.. Oncologist 2013 · PMID 23442307 · DOI 10.1634/theoncologist.2012-0279